Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122330
Filing Date
2024-11-06
Accepted
2024-11-06 16:15:26
Documents
80
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rgnx-20240930.htm   iXBRL 10-Q 2222195
2 EX-10.1 rgnx-ex10_1.htm EX-10.1 101519
3 EX-10.2 rgnx-ex10_2.htm EX-10.2 147422
4 EX-31.1 rgnx-ex31_1.htm EX-31.1 12048
5 EX-31.2 rgnx-ex31_2.htm EX-31.2 12048
6 EX-32.1 rgnx-ex32_1.htm EX-32.1 11171
7 GRAPHIC img183429381_0.jpg GRAPHIC 142251
  Complete submission text file 0000950170-24-122330.txt   10333170

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rgnx-20240930.xsd EX-101.SCH 1387877
83 EXTRACTED XBRL INSTANCE DOCUMENT rgnx-20240930_htm.xml XML 1974408
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37553 | Film No.: 241431157
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)